Rhumbline Advisers Sells 22,425 Shares of Enovis Co. (NYSE:ENOV)

Rhumbline Advisers trimmed its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 14.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,203 shares of the company's stock after selling 22,425 shares during the quarter. Rhumbline Advisers owned about 0.23% of Enovis worth $4,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Enovis by 19.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock valued at $677,000 after purchasing an additional 2,518 shares during the period. State of New Jersey Common Pension Fund D raised its stake in Enovis by 6.8% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 46,370 shares of the company's stock worth $2,035,000 after buying an additional 2,966 shares during the period. Mariner LLC raised its stake in Enovis by 16.8% during the 4th quarter. Mariner LLC now owns 7,925 shares of the company's stock worth $348,000 after buying an additional 1,142 shares during the period. Raymond James Financial Inc. acquired a new position in Enovis during the 4th quarter worth approximately $16,407,000. Finally, Swiss National Bank raised its stake in Enovis by 2.5% during the 4th quarter. Swiss National Bank now owns 109,800 shares of the company's stock worth $4,818,000 after buying an additional 2,700 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC dropped their price target on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. JMP Securities dropped their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Finally, Canaccord Genuity Group dropped their price target on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Enovis has a consensus rating of "Moderate Buy" and a consensus target price of $58.00.

Enovis Stock Up 1.1%

ENOV traded up $0.35 during midday trading on Monday, reaching $32.25. 1,186,693 shares of the company were exchanged, compared to its average volume of 834,314. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company's fifty day moving average price is $33.27 and its 200 day moving average price is $39.36. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -14.73 and a beta of 1.71. Enovis Co. has a one year low of $29.13 and a one year high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The firm had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company's revenue for the quarter was up 8.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.50 EPS. As a group, analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.